Rosuvastatin
Pro Research Analysisby 
Searched over 200M research papers for "rosuvastatin"
Rosuvastatin Lipid-Lowering Efficacy and Dose-Response
Rosuvastatin is recognized as one of the most potent statins for lowering cholesterol. Clinical trials show that doses of 10 to 40 mg per day can reduce LDL-cholesterol by 46% to 55%, with a clear linear relationship between dose and reduction in total cholesterol, LDL-cholesterol, and non-HDL-cholesterol. Compared to atorvastatin, rosuvastatin is about three times more potent in lowering LDL-cholesterol. While rosuvastatin increases HDL-cholesterol by about 7%, this effect is not dose-dependent. Short-term studies found no significant difference in withdrawal due to adverse effects between rosuvastatin and placebo, but longer-term safety data are limited Adams2017Lee2023.
Pharmacokinetics and Drug Interactions of Rosuvastatin
Rosuvastatin is typically administered once daily in doses ranging from 5 to 40 mg, with a maximum approved dose of 40 mg. It reaches peak plasma concentration about 5 hours after dosing and has a half-life of approximately 20 hours. There is significant variability in how different populations metabolize the drug, with higher clearance rates in Caucasians compared to Chinese subjects. Rosuvastatin’s systemic exposure can vary widely, and it has notable interactions with drugs such as darunavir/ritonavir, erythromycin, fluconazole, itraconazole, and antacids. The clinical significance of these interactions, especially with repeated dosing, requires further study .
Cardiovascular and Non-Lipid Benefits
Beyond cholesterol lowering, rosuvastatin has anti-inflammatory, antioxidant, and antithrombotic properties, making it valuable for both primary and secondary prevention of cardiovascular disease. It also reduces the risk of venous thromboembolism (VTE) by 47%, with this benefit consistent across various demographic and clinical subgroups, including those with or without traditional VTE risk factors Cortese2016Joseph2021.
Effects on Atherosclerosis and Plaque Stability
Rosuvastatin reduces active microcalcification in atherosclerotic plaques, as shown by imaging studies, and lowers LDL-cholesterol significantly in high-risk individuals. High-dose rosuvastatin increases the ABCA1 transporter protein in human atherosclerotic plaques, which may contribute to its anti-atherosclerotic effects through mechanisms independent of cholesterol reduction, possibly involving microRNA regulation Oliveira-Santos2024Santovito2020.
Impact on Metabolic Associated Fatty Liver Disease (MAFLD)
In patients with metabolic syndrome and moderate to severe MAFLD, rosuvastatin (10 mg/day for 52 weeks) significantly reduced liver fat content. This reduction was closely linked to decreases in LDL-cholesterol, apolipoprotein B, and free fatty acids, and the treatment was well tolerated with no significant safety concerns .
Comparative Efficacy and Safety: Rosuvastatin vs. Atorvastatin
In adults with coronary artery disease, rosuvastatin and atorvastatin provided similar protection against major cardiovascular events over three years. Rosuvastatin achieved lower LDL-cholesterol levels but was associated with a higher risk of new-onset diabetes requiring medication and a higher rate of cataract surgery compared to atorvastatin. Other safety outcomes were similar between the two drugs Lee2023Adams2017.
Additional Protective Effects
Experimental studies suggest that rosuvastatin may protect the heart from ischemia-reperfusion injury by activating protective cellular pathways and preserving mitochondrial function. It also shows promise in promoting nerve regeneration after injury, likely due to its antioxidant and anti-inflammatory properties, though more research is needed in these areas Vélez2020Abdolmaleki2020.
Conclusion
Rosuvastatin is a highly effective statin for lowering LDL-cholesterol and improving overall lipid profiles, with additional benefits in reducing cardiovascular risk, stabilizing atherosclerotic plaques, and improving liver fat in metabolic syndrome. It is generally well tolerated, but long-term safety monitoring is important, especially regarding diabetes risk and cataract development. Its non-lipid effects and potential for organ protection further support its role in cardiovascular and metabolic disease management Adams2017Cortese2016Oliveira-Santos2024+6 MORE.
Sources and full results
Most relevant research papers on this topic